Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Starting soon Not applicable

AI-Assisted Interpretation of Cardiac CT in the Emergency Department

NCT07235657 · tracked via the Priya Life Science South Korea tracker
Phase
Not applicable
Started
2025-11
Last updated
2025-11-19

Condition(s) studied

Chest PainAcute Coronary SyndromeCoronary Artery Disease

Investigational drug(s) / intervention(s)

Angiomics AI-based Coronary CT Interpretation ToolStandard CCTA Interpretation without AI

Angiomics AI-based Coronary CT Interpretation Tool: AI software integrated with the hospital PACS system to assist emergency physicians in interpreting coronary CT angiography (CCTA). The tool automatically analyzes stenosis in the left main, LAD, LCX, and RCA, and physicians use the results to guide their interpretation.

Standard CCTA Interpretation without AI: Emergency physicians independently interpret coronary CT angiography (CCTA) without access to the AI tool. Physicians evaluate stenosis in the left main, LAD, LCX, and RCA, and report diagnostic confidence using a 5-point Likert scale.

Study summary

" This prospective, pragmatic, randomized controlled trial is designed to evaluate the impact of an artificial intelligence (AI)-based coronary computed tomography angiography (CCTA) interpretation tool (Angiomics) on emergency physicians' diagnostic performance and clinical decision-making in patients presenting with acute chest pain.

CCTA is a critical diagnostic modality for suspected acute coronary syndrome (ACS) in the emergency department (ED). Accurate interpretation often requires experienced radiologists, who may not always be available, particularly during off-hours. The introduction of AI-based interpretation tools into clinical workflow has the potential to enhance diagnostic accuracy, increase physician confidence, reduce delays in decision-making, and improve efficiency of resource utilization. However, evidence regarding the real-world effectiveness of such AI tools in the ED setting remains limited.

Eligible participants will include adults aged 18 years or older presenting to the ED with chest pain and classified as intermediate risk (HEART score 4-6). Participants will be randomized into two groups: (1) AI-assisted CCTA interpretation, in which emergency physicians interpret scans with access to AI results; and (2) standard interpretation, in which emergency physicians interpret CCTA without AI support. In both groups, physicians will document the presence of stenosis in the four major coronary arteries (LM, LAD, LCX, RCA) and report diagnostic confidence on a 5-point Likert scale.

The primary outcome is the negative predictive value (NPV) of CCTA interpretation at the patient level, comparing AI-assisted versus standard interpretations against the reference standard of blinded consensus readings by board-certified radiologists. Secondary outcomes include sensitivity, specificity, positive predictive value (PPV), accuracy, diagnostic confidence, vessel-level diagnostic performance, and agreement with radiologist consensus using Cohen's Kappa.

The study aims to enroll approximately 530 participants (276 in the control arm and 254 in the intervention arm, accounting for an expected 10% dropout). Enrollment and follow-up will be conducted at Severance Hospital and Gangnam Severance Hospital over a 24-month period following IRB approval. The results are expected to provide evidence for the clinical utility and effectiveness of AI-based CCTA interpretation in the ED and to guide integration of AI into emergency care in order to optimize patient outcomes and healthcare efficiency.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Adults aged 18 years or older * Patients presenting to the emergency department with chest pain * Patients assessed as intermediate risk (Heart Score 4-6) Exclusion Criteria: * Prior history of coronary revascularization (coronary artery bypass graft surgery or stent placement) * Presence of intracardiac metallic devices such as pacemaker or prosthetic heart valves * Contraindications to contrast media (e.g., contrast allergy, severe renal impairment with eGFR \< 30 mL/min/1.73 m²) * Patients unable to cooperate (e.g., severe anxiety, non-cooperation)

Primary outcome measure(s)

  • NPV of EM physician CCTA interpretation (AI vs No AI) — During initial ED visit, at the time of CCTA interpretation
    The proportion of patients with negative CCTA findings as interpreted by emergency physicians that are confirmed as true negatives by the reference standard (blinded consensus reading by board-certified radiologists). The analysis will compare the NPV of AI-assisted interpretation versus standard interpretation without AI. Patient-level outcomes will be derived by aggregating findings across the four major coronary arteries (LM, LAD, LCX, RCA)

Trial sites (1)

FacilityCityRegionStatus
Yonsei University College of Medicine, Yonsei University Severance Hospital Seoul South Korea
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07235657 on ClinicalTrials.gov ↗ ← All trials in South Korea